Hong Kong, Dec 16, 2014 – (ACN Newswire) – China Pioneer Pharma Holdings Limited announces that, as the exclusive marketer, promotor and distributor for skin and wound cleanser NeutroPhase in mainland China and parts of Southeast Asia, the Group will offer the life- and limb-saving product, NeutroPhase, and relevant medical guidance at no charge to patients who suffer from flesh-eating disease in the region to tie in with the agreement signed between the product manufacturer – NovaBay Pharmaceuticals, Inc. and the National Necrotizing Fasciitis Foundation (NNFF) in the United States. This will enable doctors to save life of patients as quick as possible— and to curb the deterioration of the situation to avoid the need for amputation.
NeutroPhase, which has been fully tested, was pioneered by Seton Medical Center in California, United States. Among the flesh-eating disease patients that are in use of NeutroPhase , all the patients have recovered and there are no need for them to undertake amputation. NeutroPhase does not only kill bacteria, but also neutralizes the toxins produced by both bacteria and the immune system, stopping the spread of dead tissue and saving body parts from amputation. The treatment has been featured in journals like WOUNDS and other American newspaper articles. Other physicians have successfully used NeutroPhase to treat victims who suffer from flesh-eating disease reflecting fully the positive medical effectof NeutroPhase.
Mr. LI Xinzhou, Chairman, Executive Director and Chief Executive Officer of China Pioneer Pharma said: “The new treatment is especially important now because of the growing threat of flesh-eating disease caused by bacteria that have become resistant to regular antibiotics. We will cooperate together with NovaBay toprovide free NeutroPhase with step-by-step guidance to promote the new treatment. We strongly believe that NeutroPhase can bring a major improvement to the world’s medical care industry and will satisfy the enormous medical needs.”
Copyright 2014 ACN Newswire. All rights reserved.